Lockheed Martin Investment Management Co. Has $4.93 Million Stock Holdings in Boston Scientific Co. (NYSE:BSX)

Lockheed Martin Investment Management Co. decreased its holdings in shares of Boston Scientific Co. (NYSE:BSX) by 1.3% in the 4th quarter, according to its most recent 13F filing with the SEC. The fund owned 55,220 shares of the medical equipment provider’s stock after selling 740 shares during the period. Lockheed Martin Investment Management Co.’s holdings in Boston Scientific were worth $4,932,000 at the end of the most recent reporting period.

A number of other large investors also recently made changes to their positions in BSX. Jackson Wealth Management LLC lifted its stake in Boston Scientific by 1,201.1% in the fourth quarter. Jackson Wealth Management LLC now owns 51,770 shares of the medical equipment provider’s stock valued at $4,624,000 after buying an additional 47,791 shares during the period. Stratos Wealth Advisors LLC raised its position in shares of Boston Scientific by 2.3% in the 4th quarter. Stratos Wealth Advisors LLC now owns 6,569 shares of the medical equipment provider’s stock valued at $587,000 after acquiring an additional 150 shares during the period. Stratos Wealth Partners LTD. grew its holdings in Boston Scientific by 136.1% during the fourth quarter. Stratos Wealth Partners LTD. now owns 23,590 shares of the medical equipment provider’s stock valued at $2,107,000 after purchasing an additional 13,597 shares during the period. Yousif Capital Management LLC increased its stake in Boston Scientific by 2.3% in the fourth quarter. Yousif Capital Management LLC now owns 232,443 shares of the medical equipment provider’s stock valued at $20,762,000 after purchasing an additional 5,125 shares in the last quarter. Finally, 1858 Wealth Management LLC boosted its position in shares of Boston Scientific by 105.5% during the fourth quarter. 1858 Wealth Management LLC now owns 5,943 shares of the medical equipment provider’s stock worth $531,000 after purchasing an additional 3,051 shares in the last quarter. Institutional investors and hedge funds own 89.07% of the company’s stock.

Insiders Place Their Bets

In other Boston Scientific news, EVP Arthur C. Butcher sold 14,010 shares of the business’s stock in a transaction that occurred on Monday, November 25th. The shares were sold at an average price of $89.27, for a total transaction of $1,250,672.70. Following the completion of the transaction, the executive vice president now directly owns 978 shares in the company, valued at $87,306.06. The trade was a 93.47 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Edward J. Ludwig sold 4,877 shares of the firm’s stock in a transaction dated Thursday, November 21st. The shares were sold at an average price of $91.63, for a total value of $446,879.51. Following the completion of the sale, the director now directly owns 39,398 shares in the company, valued at $3,610,038.74. This trade represents a 11.02 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 47,302 shares of company stock worth $4,464,725 in the last 90 days. Company insiders own 0.50% of the company’s stock.

Analyst Ratings Changes

A number of research firms recently commented on BSX. Sanford C. Bernstein upped their price objective on shares of Boston Scientific from $92.00 to $100.00 and gave the company an “outperform” rating in a research report on Thursday, October 24th. Canaccord Genuity Group raised their price target on Boston Scientific from $98.00 to $101.00 and gave the stock a “buy” rating in a research report on Monday, December 9th. Bank of America boosted their price objective on Boston Scientific from $90.00 to $100.00 and gave the company a “buy” rating in a research report on Tuesday, October 22nd. Piper Sandler raised their target price on shares of Boston Scientific from $95.00 to $115.00 and gave the stock an “overweight” rating in a report on Monday. Finally, Raymond James upped their price target on shares of Boston Scientific from $101.00 to $119.00 and gave the company a “strong-buy” rating in a report on Friday, January 31st. One analyst has rated the stock with a hold rating, twenty-two have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the company has an average rating of “Buy” and a consensus target price of $100.39.

Boston Scientific Price Performance

Shares of Boston Scientific stock opened at $103.53 on Wednesday. The company has a 50-day simple moving average of $93.75 and a two-hundred day simple moving average of $86.53. Boston Scientific Co. has a twelve month low of $64.08 and a twelve month high of $104.25. The stock has a market capitalization of $152.58 billion, a price-to-earnings ratio of 85.56, a price-to-earnings-growth ratio of 2.68 and a beta of 0.80. The company has a quick ratio of 1.02, a current ratio of 1.48 and a debt-to-equity ratio of 0.44.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.